# Cancer Australia

Entity Resources and Planned Performance

# Cancer Australia

[Section 1: Entity Overview and Resources 254](#_Toc71464930)

[1.1 Strategic Direction Statement 254](#_Toc71464931)

[1.2 Entity Resource Statement 255](#_Toc71464932)

[1.3 Budget Measures 255](#_Toc71464933)

[Section 2: Outcomes and Planned Performance 257](#_Toc71464934)

[2.1 Budgeted Expenses and Performance 257](#_Toc71464935)

[Section 3: Budgeted Financial Statements 262](#_Toc71464936)

[3.1 Budgeted Financial Statements 262](#_Toc71464937)

[3.2 Budgeted Financial Statements Tables 263](#_Toc71464938)

## Section 1: Entity Overview and Resources

### 1.1 Strategic Direction Statement[[1]](#footnote-1)

As the Australian Government’s national cancer control agency, Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer. The Australian Government, through Cancer Australia:

* provides national leadership in cancer control
* coordinates evidence‑informed approaches with a range of healthcare providers and groups across the continuum of care
* leads the development of sustainable and effective models of cancer care
* oversees a dedicated budget for cancer research, supports clinical trial capacity and strengthens national data capacity
* provides advice on appropriate cancer care.

To achieve its aims in 2022–23, Cancer Australia will use an evidence-based approach and collaboratively engage with stakeholders to:

* lead development of an Australian Cancer Plan
* lead a shared agenda to improve cancer outcomes for Aboriginal and Torres Strait Islander people
* interpret evidence to inform development and implementation of policies and programs in cancer control
* fund cancer research in areas of identified priority
* support industry independent cancer clinical trials groups
* drive efforts to strengthen national data capacity
* provide evidence-based information and resources for consumers, health professionals and the community.

The role and functions of Cancer Australia are set out in the *Cancer Australia Act 2006*. Cancer Australia is subject to the *Public Service Act 1999* and the *Auditor‑General Act 1997*, and is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

### 1.2 Entity Resource Statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‛Budgeted expenses by outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: Cancer Australia Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Estimate** $'000 |
| **DEPARTMENTAL** |  |  |
| Prior year appropriation available | 5,452 | 4,147 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation | 11,936 | 11,242 |
| s74 retained revenue receipts (b) | 2,407 | 2,231 |
| Departmental Capital Budget (c) | 83 | 83 |
| Other services (d) |  |  |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **14,426** | **13,556** |
| **Total departmental resourcing** | **19,878** | **17,703** |
| **ADMINISTERED** |  |  |
| Prior year appropriation available | 4,367 | 4,367 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Outcome 1 | 20,451 | 18,623 |
| Other services (d) |  |  |
| Administered assets and liabilities | - | - |
| **Total administered annual appropriations** | **20,451** | **18,623** |
| **Total administered resourcing** | **24,818** | **22,990** |
| **Total resourcing for Cancer Australia** | **44,696** | **40,693** |
|  |  |  |
|  | **2021–22** | **2022–23** |
| **Average staffing level (number)** | 76 | 71 |

All figures are GST exclusive.

(a) *Appropriation Act (No. 1) 2022–23.*

(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(d) *Appropriation Act (No. 2) 2022–23.*

### 1.3 Budget Measures

This section is not applicable to Cancer Australia.

## Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to government outcomes over the Budget and forward years.

Each outcome is described within this section, together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

**Note:**

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth Performance Framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measures described in Portfolio Budget Statements will be read with broader information provided in an entity’s Corporate Plan and Annual Performance Statement – included in Annual Reports – to provide an entity’s complete performance story.

Cancer Australia’s most recent Corporate Plan and Annual Performance Statement are available at:   
www.canceraustralia.gov.au/about-us/accountability-and-reporting

### 2.1 Budgeted Expenses and Performance

**Outcome 1**

Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support

#### Program Contributing to Outcome 1

**Program 1.1: Improved Cancer Control**

#### Linked Programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health (Health)  Program 1.1: Health Research, Coordination and Access  Program 1.5: Preventive Health and Chronic Disease Support  Health has responsibility for health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future and drive further medical innovation.  Health has policy responsibility for improving the detection, treatment and survival outcomes for people with cancer. This includes oversight of cancer screening programs, such as the National Bowel Cancer Screening Program, the BreastScreen Australia Program and the National Cervical Screening Program. |

#### Budgeted Expenses for Cancer Australia

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses and Resources for Cancer Australia

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **Program 1.1: Improved Cancer Control** | | | | | |
| Administered expenses |  |  |  |  |  |
| Ordinary annual services (a) | 20,451 | 18,623 | 18,904 | 19,206 | 19,494 |
| Departmental expenses |  |  |  |  |  |
| Departmental appropriation (b) | 14,343 | 13,473 | 13,135 | 11,871 | 11,954 |
| Expenses not requiring appropriation in the Budget year (c) | 296 | 350 | 255 | 287 | 252 |
| Operating deficit (surplus) | 1,295 | 1,069 | - | - | - |
| **Total for Program 1.1** | **36,385** | **33,515** | **32,294** | **31,364** | **31,700** |
| **Total expenses for Outcome 1** | **36,385** | **33,515** | **32,294** | **31,364** | **31,700** |
|  |  |  |  |  |  |
|  | **2021–22** | **2022–23** |  |  |  |
| **Average staffing level (number)** | 76 | 71 |  |  |  |

(a) *Appropriation Act (No. 1) 2022–23.*

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)' and 'Revenue from independent sources (s74)'.

(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expenses and audit fees, interest on RoU (Right-of-Use asset) and credit applied to rental supplier expenses (rental payments).

#### Planned Performance for Cancer Australia

Table 2.1.2 details the performance measures for the program associated with Outcome 1. It also provides the related key activities as expressed in the current Corporate Plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, details of 2022–23 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance Measures for Cancer Australia

|  |  |  |
| --- | --- | --- |
| Outcome 1 | | |
| Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support. | | |
| Program Objective – Program 1.1: Improved Cancer Control | | |
| Provide national leadership in cancer control across the cancer continuum of care to minimise the impact of cancer for all Australians through development and promotion of evidence-based practice, funding cancer research and providing consumers and health professionals with cancer information and resources. | | |
| Key Activities | | |
| * Provide national leadership in cancer control. * Develop and promote evidence-based best practice cancer care. * Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies. * Provide consumer and health professional cancer information and resources. | | |
| Performance Measures | | |
| Lead a shared agenda to improve cancer outcomes for Aboriginal and Torres Strait Islander people. | | |
| Current Year 2021–22 Expected Performance Results | Budget Year 2022–23 Planned Performance Results | Forward Estimates 2023–26 Planned Performance Results |
| In alignment with Cancer Australia’s *National Aboriginal and Torres Strait Islander Cancer Framework,* and guidance from Cancer Australia’s Leadership Group on Aboriginal & Torres Strait Islander Cancer Control, Cancer Australia has:   * progressed development of the Cancer in Aboriginal and Torres Strait Islander people website * released the resource *Culturally safe communication skills – tips for non-Indigenous health professionals* * revised and updated the *Breast cancer handbook for Aboriginal and Torres Strait Islander Health Workers* * updated Aboriginal and Torres Strait Islander cancer incidence, mortality and survival data on the National Aboriginal and Torres Strait Islander Cancer Control Indicators Website. | In alignment with the *National Aboriginal and Torres Strait Islander Cancer Framework,* progress priority initiatives for Aboriginal and Torres Strait Islander people with cancer in collaboration with key stakeholders. | As per 2022–23. |
| Provide evidence-based cancer information to cancer consumers, health professionals and the community. | | |
| Current Year 2021–22 Expected Performance Results | Budget Year 2022–23 Planned Performance Results | Forward Estimates 2023–26 Planned Performance Results |
| Data and information updated across Cancer Australia’s website.  A number of new evidence-based resources were released, including resources on COVID-19 and cancer, and Aboriginal and Torres Strait Islander cancer care.  Functionality of the website was updated to enhance access to information. | Evidence-based cancer information available on the Cancer Australia website. | As per 2022–23. |
| Analyse, interpret and translate evidence to inform best practice cancer care. | | |
| Current Year 2021–22 Expected Performance Results | Budget Year 2022–23 Planned Performance Results | Forward Estimates 2023–26 Planned Performance Results |
| Published COVID-19 and cancer related information and data on Cancer Australia’s website and in journals to support best practice cancer care during the COVID-19 pandemic.  Completed a national audit of cancer research to identify the patterns and trends of cancer research funding in Australia over the period 2012–2020. | Research is translated into evidence-based information to assist and inform policy cancer care. | As per 2022–23. |
| **Fund priority cancer research through the *Priority-driven Collaborative Cancer Research Scheme.*** | | |
| Current Year 2021–22 Expected Performance Results | Budget Year 2022–23 Planned Performance Results | Forward Estimates 2023–26 Planned Performance Results |
| A total of 17 cancer research grants in areas of identified priority were awarded. | Award ≥9 cancer research grants in areas of identified priority. | As per 2022–23. |
| **Provide high quality cancer data to inform national cancer control.** | | |
| **Current Year 2021–22 Expected Performance Results** | **Budget Year 2022–23 Planned Performance Results** | **Forward Estimates 2023–26 Planned Performance Results** |
| Published data and analyses covering a range of indicators, including childhood cancer data analyses, on the National Cancer Control Indicators website.[[2]](#footnote-2) | Publish data analyses and insights on the National Cancer Control Indicators website. | As per 2022–23. |
| Material changes to Program 1.1 resulting from the following measures:  There are no material changes to Program 1.1 resulting from measures. | | |

## Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2022–23 Budget year, including the impact of Budget measures and resourcing on financial statements.

### 3.1 Budgeted Financial Statements

#### 3.1.1 Differences between Entity Resourcing and Financial Statements

This section is not applicable to Cancer Australia.

#### 3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

**Departmental Resources**

**Comprehensive Income Statement**

This statement details budgeted financial results for Cancer Australia in 2022–23.

Cancer Australia has approved operating losses of $1.295 million in 2021–22 and $1.069 million in 2022–23, net of non-appropriated depreciation and amortisation expenses, depreciation and amortisation expenses for Right-of-Use asset and lease principal repayments. A break-even position is anticipated for the forward years.

**Balance Sheet**

Assets and liabilities, excluding Land and Buildings and lease liabilities, are anticipated to remain relatively stable across the forward years. There is an anticipated decrease in Land and Buildings and lease liabilities over the forward estimates.

The increase in accumulated deficits in 2021–22 and 2022–23 reflects the approved operating losses.

**Cash Flow**

Cash flows are consistent with income, expenses and asset movements.

**Administered Resources**

Administered funding for Cancer Australia programs will continue in 2022–23. The level of administered funding across forward years represents Government expenditure on programs delivered to all Australians through Cancer Australia.

### 3.2 Budgeted Financial Statements Tables

Table 3.1: Comprehensive Income Statement (showing net cost of services) for the period ended 30 June

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **EXPENSES** |  |  |  |  |  |
| Employee benefits | 9,969 | 9,431 | 9,459 | 9,505 | 9,531 |
| Supplier expenses | 4,205 | 3,618 | 2,404 | 1,711 | 1,735 |
| Grants expenses | 900 | 900 | 650 | - | - |
| Depreciation and amortisation | 847 | 932 | 869 | 936 | 936 |
| Interest on RoU | 13 | 11 | 8 | 6 | 4 |
| Other expenses | - | - | - | - | - |
| **Total expenses** | **15,934** | **14,892** | **13,390** | **12,158** | **12,206** |
| **LESS:** |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Other revenue | 2,407 | 2,231 | 1,828 | 474 | 480 |
| **Total revenue** | **2,407** | **2,231** | **1,828** | **474** | **480** |
| **Gains** |  |  |  |  |  |
| Other | 66 | 66 | 66 | 66 | 67 |
| **Total gains** | **66** | **66** | **66** | **66** | **67** |
| **Total own-source income** | **2,473** | **2,297** | **1,894** | **540** | **547** |
| **Net cost of (contribution by) services** | **13,461** | **12,595** | **11,496** | **11,618** | **11,659** |
| Revenue from Government | 11,936 | 11,242 | 11,307 | 11,397 | 11,474 |
| **Surplus (deficit)** | **(1,525)** | **(1,353)** | **(189)** | **(221)** | **(185)** |
| **Surplus (deficit) attributable to the Australian Government** | **(1,525)** | **(1,353)** | **(189)** | **(221)** | **(185)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income** | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(1,525)** | **(1,353)** | **(189)** | **(221)** | **(185)** |
| **Note: Reconciliation of comprehensive income attributable to the agency** | | | | | |
|  | **2021–22** $'000 | **2022–23** $'000 | **2023–24** $'000 | **2024–25** $'000 | **2025–26** $'000 |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(1,525)** | **(1,353)** | **(189)** | **(221)** | **(185)** |
| plus non-appropriated expenses  depreciation and amortisation expenses | 306 | 393 | 330 | 397 | 397 |
| plus depreciation and amortisation expenses for RoU | 541 | 539 | 539 | 539 | 539 |
| less lease principal repayments | (617) | (648) | (680) | (715) | (751) |
| **Total comprehensive income (loss) attributable to the agency** | **(1,295)** | **(1,069)** | **-** | **-** | **-** |

RoU = Right-of-Use asset

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **ASSETS** |  |  |  |  |  |
| **Financial assets** |  |  |  |  |  |
| Cash and cash equivalents | 113 | 113 | 113 | 113 | 113 |
| Receivables | 4,213 | 2,960 | 2,950 | 2,940 | 2,740 |
| **Total financial assets** | **4,326** | **3,073** | **3,063** | **3,053** | **2,853** |
| **Non-financial assets** |  |  |  |  |  |
| Property, plant and equipment | 406 | 480 | 408 | 336 | 454 |
| Land and buildings | 3,910 | 3,203 | 2,496 | 1,789 | 1,082 |
| Intangibles | 187 | 155 | 157 | 93 | 28 |
| Other | 178 | 178 | 178 | 178 | 178 |
| **Total non-financial assets** | **4,681** | **4,016** | **3,239** | **2,396** | **1,742** |
| **Total assets** | **9,007** | **7,089** | **6,302** | **5,449** | **4,595** |
| **LIABILITIES** |  |  |  |  |  |
| **Payables** |  |  |  |  |  |
| Suppliers | 578 | 578 | 578 | 578 | 578 |
| Other payables | 216 | 216 | 216 | 216 | 216 |
| **Total payables** | **794** | **794** | **794** | **794** | **794** |
| **Interest bearing liabilities** |  |  |  |  |  |
| Leases | 3,758 | 3,110 | 2,430 | 1,715 | 964 |
| **Total interest bearing liabilities** | **3,758** | **3,110** | **2,430** | **1,715** | **964** |
| **Provisions** |  |  |  |  |  |
| Employees | 2,361 | 2,361 | 2,361 | 2,361 | 2,361 |
| Other provisions | 261 | 261 | 261 | 261 | 261 |
| **Total provisions** | **2,622** | **2,622** | **2,622** | **2,622** | **2,622** |
| **Total liabilities** | **7,174** | **6,526** | **5,846** | **5,131** | **4,380** |
| **Net assets** | **1,833** | **563** | **456** | **318** | **215** |
| **EQUITY** |  |  |  |  |  |
| Contributed equity | 167 | 250 | 332 | 415 | 497 |
| Reserves | - | - | - | - | - |
| Retained surpluses or (accumulated deficits) | 1,666 | 313 | 124 | (97) | (282) |
| **Total equity** | **1,833** | **563** | **456** | **318** | **215** |

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Retained earnings**   $'000 | **Asset revaluation reserve**  $'000 | **Contributed equity/ capital**  $'000 | **Total  equity**   $'000 |
| **Opening balance as at 1 July 2022** |  |  |  |  |
| Balance carried forward from previous period | 1,666 | - | 167 | **1,833** |
| Surplus (deficit) for the period | (1,353) | - | - | **(1,353)** |
| Capital budget - Bill 1 (DCB) | - | - | 83 | **83** |
| **Estimated closing balance as at 30 June 2023** | **313** | **-** | **250** | **563** |

DCB = Departmental Capital Budget

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **OPERATING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Appropriations | 13,241 | 12,495 | 11,317 | 11,407 | 11,674 |
| Net GST received | 219 | 186 | 186 | 186 | 186 |
| Other cash received | 2,407 | 2,231 | 1,828 | 474 | 480 |
| **Total cash received** | **15,867** | **14,912** | **13,331** | **12,067** | **12,340** |
| **Cash used** |  |  |  |  |  |
| Employees | 9,969 | 9,431 | 9,459 | 9,505 | 9,531 |
| Suppliers | 4,139 | 3,552 | 2,338 | 1,645 | 1,668 |
| Interest payments on lease liability | 13 | 11 | 8 | 6 | 4 |
| Grants | 900 | 900 | 650 | - | - |
| Net GST paid | 219 | 186 | 186 | 186 | 186 |
| **Total cash used** | **15,240** | **14,080** | **12,641** | **11,342** | **11,389** |
| **Net cash from (or used by) operating activities** | **627** | **832** | **690** | **725** | **951** |
| **INVESTING ACTIVITIES** |  |  |  |  |  |
| **Cash used** |  |  |  |  |  |
| Purchase of property, plant and equipment and intangibles | 93 | 267 | 92 | 93 | 282 |
| **Total cash used** | **93** | **267** | **92** | **93** | **282** |
| **Net cash from (or used by) investing activities** | **(93)** | **(267)** | **(92)** | **(93)** | **(282)** |
| **FINANCING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Capital budget - Bill 1 (DCB) | 83 | 83 | 82 | 83 | 82 |
| **Total cash received** | **83** | **83** | **82** | **83** | **82** |
| **Cash used** |  |  |  |  |  |
| Lease principal repayments | 617 | 648 | 680 | 715 | 751 |
| **Total cash used** | **617** | **648** | **680** | **715** | **751** |
| **Net cash from (or used by) financing activities** | **(534)** | **(565)** | **(598)** | **(632)** | **(669)** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 113 | 113 | 113 | 113 | 113 |
| **Cash and cash equivalents at the end of the reporting period** | **113** | **113** | **113** | **113** | **113** |

DCB = Departmental Capital Budget

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **CAPITAL APPROPRIATIONS** |  |  |  |  |  |
| Capital budget - Bill 1 (DCB) | 83 | 83 | 82 | 83 | 82 |
| **Total capital appropriations** | **83** | **83** | **82** | **83** | **82** |
| **Total new capital appropriations represented by:** |  |  |  |  |  |
| Purchase of non-financial assets | 83 | 83 | 82 | 83 | 82 |
| **Total represented by** | **83** | **83** | **82** | **83** | **82** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |  |  |  |  |  |
| Funded by capital appropriation  - DCB (a) | 83 | 83 | 82 | 83 | 82 |
| Funded internally from departmental resources | 10 | 184 | 10 | 10 | 200 |
| **Total acquisitions of  non-financial assets** | **93** | **267** | **92** | **93** | **282** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |  |  |  |  |
| Total purchases | 93 | 267 | 92 | 93 | 282 |
| **Total cash used to acquire assets** | **93** | **267** | **92** | **93** | **282** |

DCB = Departmental Capital Budget

(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of Departmental Asset Movements (Budget year   
2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings**    $'000 | **Property, plant and equipment** $'000 | **Intangibles** $'000 | **Total** $'000 |
| **As at 1 July 2022** |  |  |  |  |
| Gross book value | 1,105 | 1,928 | 1,161 | **4,194** |
| Gross book value - RoU | 4,058 | - | - | **4,058** |
| Accumulated depreciation/amortisation and impairment | (237) | (1,522) | (974) | **(2,733)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (1,016) | - | - | **(1,016)** |
| **Opening net book balance** | **3,910** | **406** | **187** | **4,503** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| Funded by capital appropriation -  DCB (a) | - | 83 | - | **83** |
| Funded internally from departmental resources | - | 144 | 40 | **184** |
| By purchase - RoU | - | - | - | **-** |
| **Total additions** | **-** | **227** | **40** | **267** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | (168) | (153) | (72) | **(393)** |
| Depreciation/amortisation expense - RoU | (539) | - | - | **(539)** |
| **Total other movements** | **(707)** | **(153)** | **(72)** | **(932)** |
| **As at 30 June 2023** |  |  |  |  |
| Gross book value | 1,105 | 2,155 | 1,201 | **4,461** |
| Gross book value - RoU | 4,058 | - | - | **4,058** |
| Accumulated depreciation amortisation and impairment | (405) | (1,675) | (1,046) | **(3,126)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (1,555) | - | - | **(1,555)** |
| **Closing net book balance** | **3,203** | **480** | **155** | **3,838** |

DCB = Departmental Capital Budget

RoU = Right-of-Use asset

(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| Grants | 14,778 | 13,028 | 13,273 | 13,442 | 13,735 |
| Suppliers | 5,673 | 5,595 | 5,631 | 5,764 | 5,759 |
| **Total expenses administered on behalf of Government** | **20,451** | **18,623** | **18,904** | **19,206** | **19,494** |
| **INCOME ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| **Non-taxation** |  |  |  |  |  |
| Other non-tax revenue | - | - | - | - | - |
| **Total non-taxation revenue** | **-** | **-** | **-** | **-** | **-** |
| **Total revenues administered on behalf of Government** | **-** | **-** | **-** | **-** | **-** |
| **Total income administered on behalf of Government** | **-** | **-** | **-** | **-** | **-** |

Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| **Financial assets** |  |  |  |  |  |
| Cash and cash equivalents | 57 | 57 | 57 | 57 | 57 |
| Receivables | 148 | 148 | 148 | 148 | 148 |
| Accrued revenue | - | - | - | - | - |
| **Total financial assets** | **205** | **205** | **205** | **205** | **205** |
| **Total assets administered on behalf of Government** | **205** | **205** | **205** | **205** | **205** |
| **LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| **Payables** |  |  |  |  |  |
| Suppliers | 75 | 75 | 75 | 75 | 75 |
| Grants | 130 | 130 | 130 | 130 | 130 |
| **Total payables** | **205** | **205** | **205** | **205** | **205** |
| **Total liabilities administered on behalf of Government** | **205** | **205** | **205** | **205** | **205** |

Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **OPERATING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Net GST received | 637 | 617 | 617 | 624 | 624 |
| Other | - | - | - | - | - |
| **Total cash received** | **637** | **617** | **617** | **624** | **624** |
| **Cash used** |  |  |  |  |  |
| Grant payments | 14,869 | 13,119 | 13,364 | 13,534 | 13,827 |
| Suppliers | 6,219 | 6,121 | 6,157 | 6,296 | 6,291 |
| **Total cash used** | **21,088** | **19,240** | **19,521** | **19,830** | **20,118** |
| **Net cash from (or used by) operating activities** | **(20,451)** | **(18,623)** | **(18,904)** | **(19,206)** | **(19,494)** |
| **Net increase (or decrease) in cash held** | **(20,451)** | **(18,623)** | **(18,904)** | **(19,206)** | **(19,494)** |
| Cash at beginning of reporting period | 57 | 57 | 57 | 57 | 57 |
| Cash from the OPA for: |  |  |  |  |  |
| - appropriations | 20,451 | 18,623 | 18,904 | 19,206 | 19,494 |
| - GST | 637 | 617 | 617 | 624 | 624 |
| Cash to the OPA |  |  |  |  |  |
| - return of GST | (637) | (617) | (617) | (624) | (624) |
| **Cash at end of reporting period** | **57** | **57** | **57** | **57** | **57** |

OPA = Official Public Account

1. For more information about the strategic direction of Cancer Australia, refer to the current Corporate Plan, available at: www.canceraustralia.gov.au/about-us/accountability-and-reporting [↑](#footnote-ref-1)
2. Available at: www.ncci.canceraustralia.gov.au [↑](#footnote-ref-2)